Ophtesia (Oxybuprocaine Hydrochloride)

Ophtesia is a topical ocular anesthetic used in procedures that involve the surface of the eye. It is employed in the following clinical situations:

• Corneal abrasion assessment: facilitates painless examination of the cornea.
• Intra‑ocular pressure measurement: enables comfortable tonometry.
• Minor ocular surgery: provides short‑lasting anesthesia for procedures such as foreign‑body removal.
• Diagnostic fluorescein staining: reduces discomfort during dye application.
• Phototherapeutic keratectomy (PTK) preparation: aids in patient comfort during pre‑treatment assessment.

• Oxybuprocaine hydrochloride blocks voltage‑gated sodium channels on peripheral sensory nerve endings in the cornea and conjunctiva. By inhibiting sodium influx, it prevents the generation and propagation of action potentials, producing a reversible loss of sensation in the ocular surface tissues.

Adverse reactions to Ophtesia are generally mild and transient, but clinicians should be aware of both common and rare events.

Common Side Effects

• Burning sensation: mild, transient irritation at the application site.
• Stinging or itching.
• Redness of the eye.
• Tearing (epiphora).
• Blurred vision: temporary loss of visual clarity.
• Conjunctival hyperemia.

Serious or Rare Side Effects

• Allergic contact dermatitis: localized swelling and rash.
• Corneal epithelial toxicity: persistent epithelial defects.
• Persistent corneal haze.
• Severe ocular inflammation.
• Vision loss: rare but reported in cases of overdose or misuse.
• Anaphylaxis: extremely rare systemic reaction.

When using Ophtesia, health professionals should consider several safety measures to minimise risk.

• Patient history: review for known hypersensitivity to ester‑type anesthetics.
• Application frequency: limit to the minimum number of doses required for the procedure.
• Contact lens wearers: advise removal of lenses before administration.
• Pediatric use: exercise caution and adjust technique for children.
• Concomitant ocular drugs: assess potential additive irritation.
• Store at room temperature: keep in the original container, protect from light and moisture.

Oxybuprocaine hydrochloride may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid)

• Combined use with other topical anesthetics: risk of cumulative toxicity.
• Concurrent administration with cytotoxic ophthalmic chemotherapy agents: may increase corneal toxicity.

Moderate Interactions (Monitor Closely)

• Use with preservative‑containing eye drops: potential for increased irritation.
• Co‑administration with anti‑inflammatory eye drops: monitor for additive effects on corneal healing.
• Interaction with systemic antihistamines: may modestly prolong anesthetic effect.
• Use with ocular lubricants containing benzalkonium chloride: watch for enhanced epithelial disruption.